Welcome to BioMarket Group!

Business Trends: Pharmaceutical Technology - Understanding your Life Science Customer (Customer Focus)

Additional Information

Published Date Dec 18, 2008
Special Offer No
Pages 74
PDF Fact Sheet View Fact Sheet for the report Business Trends: Pharmaceutical Technology - Understanding your Life Science Customer (Customer Focus) in PDF format.
Published on Date No
Format SlidePack
Publisher Datamonitor
Product Line No
Full Title No

Availability: In stock

$3,395.00

Quick Overview

In-depth interviews with 150 pharmaceutical and biotechnology companies.
Request free sample pages from Business Trends: Pharmaceutical Technology - Understanding your Life Science Customer (Customer Focus)

Introduction

This Datamonitor study examines top business challenges, IT budget outlook, and spending priorities among pharmaceutical and biotechnology companies in the US, Canada, the UK, France, Germany, Japan, China and India. It is based on the results of Datamonitor’s Business Trends primary research, conducted in Q3 and Q4 2008, with a total of 150 life science companies.

Scope

*In-depth interviews with 150 pharmaceutical and biotechnology companies

*The study focuses on business challenges, IT budget outlook, and adoption rate of SCM solutions, next-generation sequencing, and DTC marketing

*Geographic coverage includes: US, Canada, UK, France, Germany, Japan, China and India

*Respondents included IT decision-makers such as CIOs and CTOs

Highlights

Companies in the life science industry must build and maintain their product pipeline replace those drugs coming off patent so that companies can compete with generic drug manufacturers. To achieve this, companies are beginning to change their business models, albeit slow, and are investing more money into technology solutions.

IT budgets of most pharmaceutical and biotechnology companies will remain flat or increase in 2008. The current economic downturn will greatly impact the adoption of IT within the life sciences. Large organizations will look to adopt technologies to streamline back-end operations as well as help support a depleted workforce.

India and China strive to be a global leader in the pharmaceutical and biotechnology industry, and recognize that adopting IT solutions will play a large role in achieving this goal. Both these countries represent great opportunities for IT vendors.

Reasons to Purchase

*Validate your market messaging and positioning in the life science industry

*Compare pharmaceutical and biotechnology IT purchasing plans across geographies

*Identify emerging areas of concern for pharmaceutical and biotechnology companies

Executive Summary
Research Methodology
Survey Demographics
IT Spending Patterns and Adoption Trends
IT in Manufacturing: Supply Chain Management
IT in Research: Next-generation Sequencing
IT in Sales & Marketing: Patient-centric Marketing
IT Drivers, Dynamics & IT Strategy
Appendix

Request free sample pages from Business Trends: Pharmaceutical Technology - Understanding your Life Science Customer (Customer Focus)

Other selected research from the 'Markets' category:


Pharmaceuticals: Italy Industry Guide
Pharmaceuticals: Italy Industry Guide is an essential resource for top-level data and analysis covering the Italy Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis with distinct chapters for Biotechnology, Generics, OTC Pharmaceuticals and Pharmaceuticals. Learn More


The Global Multiple Sclerosis Market 2009-2024
The multiple sclerosis (MS) market has total global revenues of over $6bn in 2008. Those revenues will exceed $9bn during the second half of next decade, our new study shows. This report will provide you with the analytical information that you need to understand current trends and future directions in the MS market area, the successful drugs being introduced and where the future successful growth of the market lies. Learn More